Hanmi Science Co Ltd
008930
Company Profile
Business description
Hanmi Science Co Ltd is a Korea-based holding company. The company through its subsidiaries manufactures and distributes pharmaceutical products. The company offers prescription drugs such as neuropathic pain, obesity, epilepsy, lactobacillus intestinal supplement, oral care, hair growth, anti-inflammatory, schizophrenia, smoking cessation aid, diabetes, osteoporosis, antiemetic, vaginal contraceptive, expectorants, ophthalmic, immunosuppressant, prostatism, cancer, antitussives, vitamins and nutritional supplements, constipation, dermatology, among others.
Contact
214 Muha-ro Paltan-myeon
Gyeonggi-do
Hwaseong
KORT: +82 24109114
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 December 2025
Employees
453
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.00 | 7.10 | -0.08% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,496.55 | 120.87 | -0.47% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 42,310.49 | 121.70 | 0.29% |
| NZX 50 Index | 13,133.16 | 62.71 | 0.48% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,900.60 | 1.50 | -0.02% |
| SSE Composite Index | 3,858.13 | 17.40 | -0.45% |